Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age
Mirna Chehade(New York Proton Center), Jennifer Maloney(Regeneron (United States)), Ikuo Hirano(Northwestern University), Elizabeth Laws(Sanofi (United States)), Annamaria Farrell(Icahn School of Medicine at Mount Sinai), Jennifer D. Hamilton(Regeneron (United States)), Renata Martincova(Icahn School of Medicine at Mount Sinai), Eric Mortensen(Regeneron (United States)), Matthew P. Kosloski(AbbVie (United States)), Mohamed Kamal(Regeneron (United States)), Lila Glotfelty(Icahn School of Medicine at Mount Sinai), George D. Yancopoulos(Regeneron (United States)), Wei Keat Lim(Northwestern University), Eilish McCann(Northwestern University), Carin Samuely(Icahn School of Medicine at Mount Sinai), Marc E. Rothenberg(Cincinnati Children's Hospital Medical Center), Ruiqi Liu(Sun Yat-sen University), Robert D. Pesek(Arkansas Children's Hospital), Arsalan Shabbir(Northwestern University), Margaret H. Collins(Icahn School of Medicine at Mount Sinai), Evan S. Dellon(Icahn School of Medicine at Mount Sinai), Naimish Patel(Sanofi (United States)), Jonathan M. Spergel(Icahn School of Medicine at Mount Sinai), Matthew F. Wipperman(Cornell University)
Cited by 107
Related Papers
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
Eosinophilic esophagitis: Updated consensus recommendations for children and adults
|Journal of Allergy and Clinical Immunology|2011|2.1k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
VEGF-Trap: A VEGF blocker with potent antitumor effects
|Proceedings of the National Academy of Sciences|2002|1.7k
Angiopoietin-1 protects the adult vasculature against plasma leakage
|Nature Medicine|2000|1.3k